Non-invasive actionable biomarkers for metastatic prostate cancer

In the current clinical setting, many disease management options are available for men diagnosed with prostate cancer. For metastatic prostate cancer, first-line therapies almost always involve agents designed to inhibit androgen receptor (AR) signaling. Castration-resistant prostate cancers (CRPCs)...

Descripción completa

Detalles Bibliográficos
Autor principal: Luo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2016
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730867/
https://www.ncbi.nlm.nih.gov/pubmed/29264186
http://dx.doi.org/10.1016/j.ajur.2016.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730867/
https://www.ncbi.nlm.nih.gov/pubmed/29264186
http://dx.doi.org/10.1016/j.ajur.2016.09.003

Ejemplares similares